Baseline demographic and clinical characteristics of patients are shown in Table 1. In the study population, 60.0% of patients had STEMI. Furthermore, 6.7% of patients had severe cardiovascular disease, classified as Killip Class IV. These patients were excluded from PRASFIT-ACS , a phase III clinical trial conducted in Japanese patients with ACS.Table 1Baseline demographic and clinical characteristics of patientsPRASFIT-Practice I N (%)(N = 732)[Reference]PRASFIT-ACS N (%)(N = 685)Sex Male560 (76.5)536 (78.2)Age (years) ≥75221 (30.2)165 (24.1) Mean ± SD67.0 ± 12.465.4 ± 11.4 Median (range)67 (29–97)65 (32–95)Body weight (kg) ≤5094 (12.8)85 (12.4) Mean ± SD63.8 ± 12.564.2 ± 12.3Final diagnosis STEMI439 (60.0)340 (49.6) NSTEMI92 (12.6)187 (27.3) Unstable angina198 (27.0)156 (22.8)Killip classification Class I572 (78.1)NA Class II91 (12.4) Class III15 (2.0) Class IV49 (6.7)Exclusion criteriaMedical history Prior MI71 (9.7)34 (5.0) Prior revascularizations92 (12.6)40 (5.8) Prior CABG7 (1.0)6 (0.9) Prior TLR33 (4.5)15 (2.2) Prior ischemic stroke37 (5.1)Exclusion criteriaComplications Hypertension559 (76.4)495 (72.3) Dyslipidemia565 (77.2)516 (75.3) Diabetes mellitus267 (36.5)250 (36.5) History of smoking249 (34.0)273 (39.9) On dialysis15 (2.0)Exclusion criteriaAntithrombotic agent Prasugrel + aspirin678 (92.6)685 (100.0) Prasugrel + aspirin + WF or DOAC19 (2.6)Exclusion criteria Prasugrel + NSAIDs (w/o aspirin)11 (1.5)Exclusion criteriaConcomitant drug PPIs347 (47.4)282 (41.2)Stent type Drug-eluting stent671 (91.7)291 (42.5)Puncture site Brachial23 (3.1)22 (3.2) Radial374 (51.1)285 (41.6) Femoral315 (43.0)366 (53.4) SD standard deviation, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction, MI myocardial infarction, CABG coronary artery bypass graft, TLR target lesion revascularization, WF warfarin, DOAC direct oral anti-coagulant, NSAIDs non-steroidal anti-inflammatory drugs, PPIs proton pump inhibitors, NA not available